SITC Archive Library

Back to Library

iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development 

02-23-2018 09:19

Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development
July 29, 2006
The Doubletree Rockville Hotel in Rockville, Maryland

Program Organizers
Bernard A. Fox, PhD - Earle A. Chiles Research Institute
Thomas F. Gajewski, MD, PhD - University of Chicago
Rachel W. Humphrey, MD - Bristol Myers-Squibb Company
Craig L. Slingluff, Jr., Md - University of Virginia
Jon M. Wigginton, MD - Merck & Co., Inc.

Program Summary
The goal of this program was to recruit a group of individuals to help develop topics for a full Fall 2017 iSBTc workshop.

Presentations and video recordings are available based on permission from presenters.


#PresentationSlides #SITC #CombinationTherapy #AlliedHealth #Clinician #Industry #Oncologist #Researcher #2006 #ClinicalTrials #BreastCancers #Lymphoma #Melanoma #OvarianCancer #ProstateCancer #AdoptiveCellTherapy
#Cytokines #ImmuneCheckpointInhibitors #TherapeuticAntibodies #Vaccines #AdverseEvents #Toxicities

Statistics
0 Favorited
15 Views
17 Files
0 Shares
22 Downloads
​
Attachment(s)
Download All
pdf file
Perspectives on Combination Therapies from the NCI   2.05 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Leadership Perspectives on Biological Combinations; Presentation: Perspectives on Combination Therapies from the NCI; Presenter: Robert H. Wiltrout, PhD - National Cancer Institute; Date: July 29, 2006
 
Download
pdf file
FDA Perspectives on Combination Therapy of Cancer   280 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Leadership Perspectives on Biological Combinations; Presentation: FDA Perspectives on Combination Therapy of Cancer; Presenter: Raj Puri, MD, PhD - Food and Drug Administration; Date: July 29, 2006
 
Download
pdf file
Clinical Cancer Research - The Importance of Translationa...   1.39 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Leadership Perspectives on Biological Combinations; Presentation: Clinical Cancer Research - The Importance of Translational Research; Presenter: Alexander M. Eggermont, MD, PhD - Erasmus University Medical Center; Date: July 29, 2006
 
Download
pdf file
Opportunities and Obstacles - Academic Perspective   2.15 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Opportunities and Obstacles to Developing Novel Biological Combinations; Presentation: Opportunities and Obstacles - Academic Perspective; Presenter: Michael B. Atkins, MD - Beth Israel Deaconess Medical Center; Date: July 29, 2006
 
Download
pdf file
Opportunities and Obstacles - Industry Perspective   38 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Opportunities and Obstacles to Developing Novel Biological Combinations; Presentation: Opportunities and Obstacles - Industry Perspective; Presenter: Geoffrey M. Nichol, MD, MBA - Medarex, Inc.; Date: July 29, 2006
 
Download
pdf file
Opportunities and Obstacles - Regulatory Perspective   98 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Opportunities and Obstacles to Developing Novel Biological Combinations; Presentation: Opportunities and Obstacles - Regulatory Perspective; Presenter: Steven Hirschfeld, MD, PhD - Food and Drug Administration; Date: July 29, 2006
 
Download
pdf file
Combination Therapies   1.69 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: State-of-the-Art; Presentation: Combination Therapies; Presenters: Thomas F. Gajewski, MD, PhD - University of Chicago, James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center, Drew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine, Jon M. Wigginton, MD - Merck & Co., Inc.; Date: July 29, 2006
 
Download
pdf file
STAT3 Signaling Regulates Crosstalk between the Tumor an...   289 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: State-of-the-Art; Presentation:Combination Immune-Antiangiogenic Therapy: STAT3 Signaling Regulates Crosstalk between the Tumor and Its Immune Microenvironment; Presenters: Kim A. Margolin, MD - City of Hope; Date: July 29, 2006
 
Download
pdf file
Lessons from Ovarian Cancer   1.09 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: State-of-the-Art; Presentation: Combination Immune-Antiangiogenic Therapy: Lessons from Ovarian Cancer; Presenters: George Coukos, MD, PhD - University of Pennsylvania; Date: July 29, 2006
 
Download
pdf file
A DNA Vaccine Against Tumor Stromal Antigen FAP Boosts C...   1.09 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: State-of-the-Art; Presentation: Combination Immune-Antiangiogenic Therapy: A DNA Vaccine Against Tumor Stromal Antigen FAP Boosts Chemotherapy; Presenters: Ralph A. Reisfeld, MD - The Scripps Research Institute; Date: July 29, 2006
 
Download
pdf file
Combination Immune Therapy-Modulator of Apoptosis   1.24 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: State-of-the-Art; Presentation: Combination Immune Therapy-Modulator of Apoptosis; Presenters: James H. Finke, PhD - Cleveland Clinic Foundation, Crystal Mackall, MD - National Cancer Institute, James W. Mier, MD - Beth Israel Deaconess Medical Center, Craig L. Slingluff, Jr., MD - University of Virginia; Date: July 29, 2006
 
Download
pdf file
Combination Immune Therapy - Chemotherapy   1.39 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: State-of-the-Art; Presentation: Combination Immune Therapy - Chemotherapy; Presenters: Elizabeth M. Jaffee, MD - Johns Hopkins University, Jared A. Gollob, MD - Duke University, John M. Kirkwood, MD - University of Pittsburgh Cancer Institute, James C. Yang, MD - National Cancer Institute; Date: July 29, 2006
 
Download
pdf file
Systemic Therapy of Melanoma - Current Approved Options   1.48 MB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: State-of-the-Art; Presentation: Combination Immune Therapy: Systemic Therapy of Melanoma - Current Approved Options; Presenters: John M. Kirkwood, Md - University of Pittsburgh Cancer Institute; Date: July 29, 2006
 
Download
pdf file
Scientific Barriers to Investigation of Novel Combinations   50 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Facilitated Concurrent Breakout Sessions; Presentation: Breakout 1: Scientific Barriers to Investigation of Novel Combinations; Presenters: Bernard A. Fox, PhD - Earle A. Chiles Research Institute, Michael T. Lotze, MD - University of Pittsburgh, William J. Murphy, PhD - University of Nevada School of Medicine, Nicolas P. Restifo, MD - National Cancer Institute; Date: July 29, 2006
 
Download
pdf file
Clinical Trial Design and Development of Combinations   65 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Facilitated Concurrent Breakout Sessions; Presentation: Breakout 2: Clinical Trial Design and Development of Combinations; Presenters: Rachel W. Humphrey, MD -Bristol Myers-Squibb Company, Carl H. June, MD - University of Pennsylvania, Ulrich Keilholz, MD - Charité, CBF, Berlin, Walter J. Urba, MD, PhD - Earle A. Chiles Research Institute; Date: July 29, 2006
 
Download
pdf file
Regulatory Issues and the Development of Combinations   29 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Facilitated Concurrent Breakout Sessions; Presentation: Breakout 3: Regulatory Issues and the Development of Combinations; Presenters: Jeffrey S. Weber, MD, PhD - Norris Cancer Center, Ashok Batra, MD - Food and Drug Administration/CBER, Alexander M. Eggermont, MD, PhD - Erasmus University Medical Center, David Ross, MD - Food and Drug Administration/CDER; Date: July 29, 2006
 
Download
pdf file
Intellectual Property Barriers to the Development of Com...   31 KB   1 version
Uploaded - 02-23-2018
Meeting: iSBTc Combination Therapy for Cancer Workshop: Opportunities and Obstacles for Future Development; Session: Facilitated Concurrent Breakout Sessions; Presentation: Breakout 4: Intellectual Property Barriers to the Development of Combinations; Presenters: Kathleen Sybert, PhD, Esq. - Clinical Technology Transfer Group, Edward Berg - Bristol Myers-Squibb Company; Date: July 29, 2006
 
Download